In this study, we rationally combined the alkylating chemotherapeutic CTX with GITR agonist antibodies, which led to potent and durable antitumor responses in several clinically relevant models, including MPC-11 plasmacytoma and the poorly immunogenic B16 melanoma. Here, TNFRSF18 is linked to plasmacytoma.